"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease

Journal of Crohn's and Colitis

Volumn 7, Issue 6, 2013, Pages 441-450

  Cossu, Andrea ^a,c   Biancone, Livia ^b   Ascolani, Marta ^b   Pallone, Francesco ^b   Boirivant, Monica ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Apoptosis; Azathioprine; Crohn's Disease; IFN

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; MERCAPTOPURINE; MESALAZINE; PREDNISONE; TIOGUANINE;

ADULT; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LEUKOPENIA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; VIRUS HEPATITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; AZATHIOPRINE; BUDESONIDE; CELLS, CULTURED; CROHN DISEASE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; MESALAMINE; MIDDLE AGED; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84877043265     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.06.020     Document Type: Article

References (20)

1. Fraser A.G., Orchard T.R., Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30-year review. Gut 2002, 50:485-489.
2. Prefontaine E., MacDonald J.K., Sutherland L.R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010, 6:CD000545.
3. Khan K.J., Dubinsky M.C., Ford A.C., Ullman T.A., Talley N.J., Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011, 106:630-642.
4. Rutgeerts P. Review article: treatment of perianal fistulizing Crohn's disease. Aliment Pharmacol Ther 2004, 20(Suppl. 4):106-110.
5. Prefontaine E., Sutherland L.R., MacDonald J.K., Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, 4:CD000067.
6. Peyrin-Biroulet L., Deltenre P., Ardizzone S., D'Haens G., Hanauer S.B., Herfarth H., et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009, 104:2089-2096.
7. Reinisch W., Angelberger S., Petritsch W., Shonova O., Lukas M., Bar-Meir S., et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010, 59:752-759.
8. Present D.H., Meltzer S.J., Krumholz M.P., Wolke A., Korelitz B.I. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 1989, 111:641-649.
9. Etchevers M.J., Aceituno M., Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol 2008, 14:5512-5518.
10. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
11. Wright S., Sanders D.S., Lobo A.J., Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004, 53:1123-1128.
12. Osterman M.T., Kundu R., Lichtenstein G.R., Lewis J.D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130:1047-1053.
13. González-Lama Y., Bermejo F., López-Sanromán A., García-Sánchez V., Esteve M., Cabriada J.L., et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011, 34:544-554.
14. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4 T lymphocytes. J Clin Invest 2003, 111:1133-1145.
15. Boirivant M., Marini M., Di Felice G., Pronio A.M., Montesani C., Tersigni R., et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999, 116:557-565.
16. Neurath M.F., Kiesslich R., Teichgräber U., Fischer C., Hofmann U., Eichelbaum M., et al. 6-Thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol 2005, 3:1007-1014.
17. Dignass A., Van Assche G., Lindsay J.O., Lémann M., Söderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
18. Cuffari C., Li D.Y., Mahoney J., Barnes Y., Bayless T.M. Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-g production in patients with Crohn's disease on AZA therapy. Dig Dis Sci 2004, 49:133-137.
19. Ansari A., Hassan C., Duley J., Marinaki A., Shobowale-Bakre E.M., Seed P., et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1743-1750.
20. Lennard L., Davies H.A., Lilleyman J.S. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?. Br J Cancer 1993, 68:186-190.